Categories: Top News

ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Allarity Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ALLR

NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Allarity Therapeutics, Inc. (NASDAQ: ALLR) between May 17, 2022 and July 19, 2024, both dates inclusive (the “Class Period”), of the important November 12, 2024 lead plaintiff deadline.

SO WHAT: If you purchased Allarity securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Allarity class action, go to https://rosenlegal.com/submit-form/?case_id=27420 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 12, 2024. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit,  throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) defendants had overstated the Dovitinib, Allarity’s drug candidate which treats renal cell carcinoma, new drug application’s (“NDA”) continued regulatory prospects; (2) Allarity and three of its former officers had engaged in illegal, illicit, and/or otherwise improper conduct in connection with the Dovitinib NDA and/or the Dovitinib-DRP premarket approval application (“PMA”); (3) the foregoing misconduct subjected Allarity to an increased risk of regulatory and/or governmental scrutiny and enforcement action, as well as significant legal, monetary, and reputational harm; (4) following Allarity’s announcement that it was, in fact, being investigated for wrongdoing in connection with the Dovitinib NDA and/or the Dovitinib-DRP PMA, Allarity downplayed the substantial likelihood that an enforcement action would result from such investigation; and (5) as a result, Allarity’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Allarity class action, go to https://rosenlegal.com/submit-form/?case_id=27420 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        case@rosenlegal.com
        www.rosenlegal.com

GlobeNewswire

GlobeNewswire, is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Recent Posts

Everbright Digital Holding Limited Announces Closing of Initial Public Offering

HONG KONG, April 21, 2025 (GLOBE NEWSWIRE) -- Everbright Digital Holding Limited (the “Company” or…

25 minutes ago

NorthEast Community Bancorp, Inc. Reports Results for the Three Months Ended March 31, 2025

WHITE PLAINS, N.Y., April 21, 2025 (GLOBE NEWSWIRE) -- NorthEast Community Bancorp, Inc. (Nasdaq: NECB)…

1 hour ago

OWNx Launches Industry-First “EDGE” Membership: Buy Gold, Silver, and Platinum At-Cost with Zero Fees

OWNx, a pioneer in precious metals investment since 2008, today announced the launch of OWNx…

2 hours ago

VitalSource Acquires RedShelf

Raleigh, NC, April 21, 2025 (GLOBE NEWSWIRE) -- VitalSource announced today it has acquired RedShelf,…

2 hours ago

Eurasian Resources Group refutes negotiations to sell the Company

LUXEMBOURG, April 21, 2025 (GLOBE NEWSWIRE) -- In response to a number of media speculations…

2 hours ago

CEYLON GRAPHITE CORP ANNOUNCES PROPOSED SHARE FOR DEBT TRANSACTION

Toronto, April 21, 2025 (GLOBE NEWSWIRE) -- Ceylon Graphite Corp. (TSXV: CYL) (“Ceylon” or the…

3 hours ago

This website uses cookies.